Petros Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
PTPI Nasdaq 8731 https://www.petrospharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Petros Pharmaceuticals Inc

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) - Sep 11th, 2024 1:15 pm
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Sep 3rd, 2024 1:00 pm
Petros Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations - Aug 17th, 2024 1:56 pm
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) - Jul 29th, 2024 1:20 pm
Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance - Jul 16th, 2024 1:00 pm
Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch - May 29th, 2024 1:00 pm
Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA - May 21st, 2024 1:15 pm
Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe - May 14th, 2024 1:15 pm
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals - May 14th, 2024 11:00 am
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health - Apr 23rd, 2024 1:15 pm
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil) - Apr 16th, 2024 1:15 pm
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status - Apr 2nd, 2024 1:15 pm
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider - Mar 19th, 2024 1:00 pm
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider - Feb 14th, 2024 2:15 pm
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch - Jan 24th, 2024 2:15 pm
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch - Jan 17th, 2024 2:00 pm
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status - Dec 12th, 2023 3:00 pm
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider - Dec 12th, 2023 2:15 pm
Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R) - Oct 30th, 2023 1:15 pm